GBM radiosensitizers: dead in the water
or just the beginning?
J Neurooncol
; 134(3): 513-521, 2017 Sep.
Article
em En
| MEDLINE
| ID: mdl-28762004
ABSTRACT
The finding that most GBMs recur either near or within the primary site after radiotherapy has fueled great interest in the development of radiosensitizers to enhance local control. Unfortunately, decades of clinical trials testing a wide range of novel therapeutic approaches have failed to yield any clinically viable radiosensitizers. However, many of the previous radiosensitizing strategies were not based on clear pre-clinical evidence, and in many cases blood-barrier penetration was not considered. Furthermore, DNA repair inhibitors have only recenly arrived in the clinic, and likely represent potent agents for glioma radiosensitization. Here, we present recent progress in the use of small molecule DNA damage response inhibitors as GBM radiosensitizers. In addition, we discuss the latest progress in targeting hypoxia and oxidative stress for GBM radiosensitization.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Radiossensibilizantes
/
Neoplasias Encefálicas
/
Glioblastoma
/
Recidiva Local de Neoplasia
Tipo de estudo:
Etiology_studies
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article